🇺🇸 FDA
Company

RIGEL

RIGEL PHARMACEUTICALS INC

RIGL pharma USA

Quick answer

RIGEL is a pharma company (RIGL) headquartered in SOUTH SAN FRANCISCO, CA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Fostamatinib

Covid19

Phase 3 · small_molecule · completed

1 trials project

Fostamatinib disodium

Warm Antibody Autoimmune Hemolytic Anemia

Phase 3 · small_molecule · active

2 trials project

Fostamatinib disodium

Immune Thrombocytopenic Purpura

Phase 3 · small_molecule · completed

3 trials project

Fostamatinib

Myelofibrosis

Phase 2 · small_molecule · terminated

1 trials project

Fostamatinib

Hidradenitis Suppurativa

Phase 2 · small_molecule · completed

1 trials project

Fostamatinib 150 mg

IGA Nephropathy

Phase 2 · small_molecule · completed

1 trials project

Fostamatinib 150 mg bid

Warm Antibody Autoimmune Hemolytic Anemia

Phase 2 · small_molecule · completed

1 trials project

Fostamatinib Disodium

T Cell Lymphoma

Phase 2 · small_molecule · completed

1 trials project

Fostamatinib Disodium (R935788)

Systemic Lupus Erythematosus

Phase 2 · small_molecule · terminated

1 trials project

Fostamatinib Disodium / R935788

Purpura, Thrombocytopenic, Idiopathic

Phase 2 · small_molecule · completed

1 trials project

Fostamatinib Disodium tablet 100 mg

IGA Nephropathy

Phase 2 · small_molecule · terminated

1 trials project

Fostamatinib disodium (R935788)

Rheumatoid Arthritis

Phase 2 · small_molecule · completed

2 trials project

LY3871801

Rheumatoid Arthritis

Phase 2 · small_molecule · completed

1 trials project

Olutasidenib

Acute Myeloid Leukemia

Phase 2 · small_molecule · active

1 trials project

Olutasidenib

Targeted Therapy

Phase 2 · small_molecule · active

1 trials project

Olutasidenib

Myelodysplastic Syndromes

Phase 2 · small_molecule · active

1 trials project

Olutasidenib

Mutant IDH1 Inhibitor Olutasidenib

Phase 2 · small_molecule · active

1 trials project

Olutasidenib

Chronic Myelomonocytic Leukemia

Phase 2 · small_molecule · terminated

1 trials project

Olutasidenib + TMZ

High Grade Glioma

Phase 2 · small_molecule · active

1 trials project

Placebo

Asthma

Phase 2 · small_molecule · completed

1 trials project

Placebo

Acute Respiratory Distress Syndrome

Phase 2 · small_molecule · active

1 trials project

R348 Ophthalmic Solution, 0.2%

Chronic Graft-versus-host Disease

Phase 2 · small_molecule · completed

1 trials project

R348 Ophthalmic Solution, 0.2%

Keratoconjunctivitis Sicca

Phase 2 · small_molecule · completed

2 trials project

R788

Rheumatoid Arthritis

Phase 2 · small_molecule · completed

1 trials

Drugs (3)

drug

fostamatinib disodium

TAVALISSE

 drug

olutasidenib

REZLIDHIA

 drug

pralsetinib

GAVRETO

Patents (8)

patent

US 12384775

Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12357623

Method for treating a disease or condition using a pyrazole compound or formulat

Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12331036

Heterocyclic RIP1 kinase inhibitors

Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12297202

RIP1K inhibitors

Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12263180

Method for treatment of COVID-19-associated conditions

Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12227508

TGF-β inhibitors

Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12156880

Heterocyclic RIP1 kinase inhibitors

Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12116354

RIP1 inhibitory compounds and methods for making and using the same

Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)